Skip to content

Study · Observational study · n = 393 · 2026

8 results

Real-world use of semaglutide for obesity treatment: A cohort study in an integrated health care delivery system.

Baalmann A, Michel J, Avedissian SN, Pow A, Farris K

Journal of managed care & specialty pharmacy1 Jun 2026Cited by 2 (Europe PMC)

PMID42166306 (opens in a new tab)PMCIDPMC13193313 (opens in a new tab)DOI10.18553/jmcp.2026.32.6.660 (opens in a new tab)PepBankPUB-42166306
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanObservational studyOther

    In patients using semaglutide for obesity in a health system, 44% (172) remained persistent through 12 months.

    In plain wordsIn real-world patients using semaglutide for obesity, fewer than half stayed on treatment for 12 months.

    Peptide
    Semaglutide
    Outcome
    Not applicablePersistence to therapy at 12 months
    Study

    n = 393

    Analysis
    Primary
    Outcome group
    Treatment adherence and retention · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Persistent patients
    44%
    12 months

    Source sentences

    Summary
    Throughout the 12-month follow-up period, 44% (172) of patients remained persistent
    2 context sentences
    Summary · context
    This retrospective, cohort, observational study evaluated prescription and clinical data from a single health system between 2021 and 2024.
    Summary · context
    A total of 393 patients were included.
  2. 02HumanObservational studyOther

    In patients using semaglutide for obesity, 44% (175) were adherent at 12 months.

    In plain wordsIn real-world patients using semaglutide for obesity, fewer than half took it as prescribed over 12 months.

    Peptide
    Semaglutide
    Outcome
    Not applicableAdherence at 12 months
    Study

    n = 393

    Analysis
    Secondary
    Outcome group
    Treatment adherence and retention · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Adherent patients
    44%
    12 months

    Source sentences

    Summary
    At 12 months, 44% (175) patients were adherent
    2 context sentences
    Summary · context
    This retrospective, cohort, observational study evaluated prescription and clinical data from a single health system between 2021 and 2024.
    Summary · context
    A total of 393 patients were included.
  3. 03HumanObservational studyEfficacy outcome

    In patients using semaglutide for obesity, persistent patients lost a mean of 13.8% of baseline weight, compared with 6.4% for nonpersistent patients.

    In plain wordsPatients who stayed on semaglutide for obesity lost more weight than those who stopped early.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss in persistent vs nonpersistent patients
    Study

    n = 393

    Comparator
    Nonpersistent patients
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Mean weight loss
    13.8%
    persistent
    Mean weight loss
    6.4%
    nonpersistent

    Source sentences

    Summary
    and lost a mean of 13.8% of their baseline weight, compared with 6.4% for nonpersistent patients.
    2 context sentences
    Summary · context
    This retrospective, cohort, observational study evaluated prescription and clinical data from a single health system between 2021 and 2024.
    Summary · context
    A total of 393 patients were included.
  4. 04HumanObservational studyOther

    In patients using semaglutide for obesity, female sex was associated with lower odds of persistence than male sex (odds ratio 0.32).

    In plain wordsWomen using semaglutide for obesity were linked to a lower chance of staying on treatment than men.

    Peptide
    Semaglutide
    Outcome
    DecreasePersistence by sex
    Study

    n = 393

    Comparator
    Male sex
    Outcome group
    Treatment adherence and retention · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Odds ratio persistence
    0.32 OR
    female vs male

    Source sentences

    Summary
    compared with male sex, female sex was associated with lower odds of persistence (odds ratio = 0.32; 95% CI = 0.14-0.75)
    2 context sentences
    Summary · context
    This retrospective, cohort, observational study evaluated prescription and clinical data from a single health system between 2021 and 2024.
    Summary · context
    A total of 393 patients were included.
  5. 05HumanObservational studyOther

    In patients using semaglutide for obesity, female sex was associated with lower odds of adherence than male sex (odds ratio 0.33).

    In plain wordsWomen using semaglutide for obesity were linked to a lower chance of taking it as prescribed than men.

    Peptide
    Semaglutide
    Outcome
    DecreaseAdherence by sex
    Study

    n = 393

    Comparator
    Male sex
    Outcome group
    Treatment adherence and retention · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Odds ratio adherence
    0.33 OR
    female vs male

    Source sentences

    Summary
    and adherence (odds ratio = 0.33; 95% CI = 0.14-0.77)
    2 context sentences
    Summary · context
    This retrospective, cohort, observational study evaluated prescription and clinical data from a single health system between 2021 and 2024.
    Summary · context
    A total of 393 patients were included.
  6. 06HumanObservational studyOther

    In patients using semaglutide for obesity, race, ethnicity and comorbidities were not statistically significantly associated with persistence or adherence.

    In plain wordsAmong patients using semaglutide for obesity, race, ethnicity and other health conditions were not linked to staying on treatment.

    Peptide
    Semaglutide
    Outcome
    No significant changePersistence and adherence by race, ethnicity and comorbidities
    Study

    n = 393

    Outcome group
    Treatment adherence and retention · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    whereas race, ethnicity, and comorbidities were not statistically significantly associated with persistence or adherence.
    2 context sentences
    Summary · context
    This retrospective, cohort, observational study evaluated prescription and clinical data from a single health system between 2021 and 2024.
    Summary · context
    A total of 393 patients were included.
  7. 07HumanObservational studyEfficacy outcome

    In patients using semaglutide for obesity, adherent patients experienced 13% weight loss at 12 months.

    In plain wordsPatients who took semaglutide for obesity as prescribed lost weight over 12 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss in adherent patients
    Study

    n = 175

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Weight loss
    13%
    adherent

    Source sentences

    Summary
    and experienced 13% weight loss.
    2 context sentences
    Summary · context
    This retrospective, cohort, observational study evaluated prescription and clinical data from a single health system between 2021 and 2024.
    Summary · context
    A total of 393 patients were included.
  8. 08HumanObservational studyEfficacy outcome

    In patients using semaglutide for obesity, closely following the approved titration schedule gave 12.5% average weight loss at month 12, versus 7.2% with other titration patterns.

    In plain wordsPatients who followed the approved semaglutide dose schedule lost more weight than patients who used other dose patterns.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss by titration schedule
    Study

    n: not reported in source

    Comparator
    Other titration patterns
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Average weight loss
    12.5%
    approved titration
    Average weight loss
    7.2%
    other titration patterns

    Source sentences

    Summary
    For those closely following the approved titration schedule, a 12.5% average weight loss at month 12 was observed, almost double that of patients using other titration patterns (7.2% average weight loss at month 12).
    2 context sentences
    Summary · context
    This retrospective, cohort, observational study evaluated prescription and clinical data from a single health system between 2021 and 2024.
    Summary · context
    A total of 393 patients were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.